Brought to you by 
BioDirection gets Harvard nanowire IP from Nanosys
01 May 2012
Executive Summary
Nanosys Inc. (molecular materials to improve LCD backlighting and battery storage capacity) has licensed BioDirection Inc. (point-of-care brain injury screening) exclusive global rights to Harvard University-originated nanowire IP, which BioDirection will use to develop biosensors employed in brain injury detection or monitoring devices.
Deal Industry
- Medical Devices
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioDirection gets Harvard nanowire IP from Nanosys
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice